Caris Life Sciences was founded in 1996 by David Halbert. After raising $130 million in fresh capital in 2021, CFO Thomas Parker told reporters that the company is considering an IPO. "The size of the company’s scale, our future pipeline — some of those things — are pretty well suited for the public markets," he said. "We're taking a serious look at that this year. That doesn’t mean we have definite plans."

Caris Life Sciences is a medical technology company that specializes in molecular profiling, using AI to guide personalized cancer treatments. In 2021, the company announced an $830 million growth equity round, bringing its total funding to $1.3 billion. Investors include Sixth Street Partners, Canada Pension Plan Investment Board, ClearBridge Investments, and Coatue Management. Caris announced a post-money valuation of $7.83 billion.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Caris Life Sciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Caris Life Sciences

Forge green plus iconForge green minus icon

What is Caris Life Sciences's IPO price?

The IPO price for Caris Life Sciences will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Caris Life Sciences?

Caris Life Sciences is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Caris Life Sciences shares pre-IPO?

If you own Caris Life Sciences pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Caris Life Sciences a publicly traded company?

Caris Life Sciences is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Caris Life Sciences's funding to date?

Caris Life Sciences has raised $465MM to date.
Forge green plus iconForge green minus icon

When was Caris Life Sciences founded?

Caris Life Sciences was founded in 2008.

Who are Caris Life Sciences's major investors?

Coatue Management
Fidelity Management & Research
T. Rowe Price
Neuberger Berman
Silver Lake
Rock Springs Capital
Sixth Street Partners
Millennium Management
J.H. Whitney Capital Partners
Updated on: May 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.